ICD J84.81ORPHA:538LAM

Lymphangioleiomyomatosis

Lymphangioleiomyomatosis (LAM) is a rare progressive lung disease that almost exclusively affects women, causing cystic lung destruction, breathlessness, and recurrent pneumothorax. It is caused by mutations in TSC genes. The mTOR inhibitor sirolimus slows progression and is the only approved treatment.

422
Articles
264
Trials (13 AU)
Updated
26 March 2026
Loading...

Common Questions

What is Lymphangioleiomyomatosis?

Lymphangioleiomyomatosis (LAM) is a rare progressive lung disease that almost exclusively affects women, causing cystic lung destruction, breathlessness, and recurrent pneumothorax. It is caused by mutations in TSC genes. The mTOR inhibitor sirolimus slows progression and is the only approved treatment.

How many clinical trials are available for Lymphangioleiomyomatosis?

RareWays currently indexes 264 clinical trials for Lymphangioleiomyomatosis, of which 23 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.

Where does the research data for Lymphangioleiomyomatosis come from?

RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.

Get research updates

Monthly email when new findings are published for Lymphangioleiomyomatosis.

No spam. Unsubscribe any time. Not medical advice.

This information is for general awareness only.

For guidance specific to your situation, please speak with your healthcare team.